Data on 84,622 type 2 diabetes patients showed those on exogenous insulin treatment had a higher risk of complications — including major cardiovascular events, renal conditions, cancer and all-cause mortality — than those who were on other glucose-lowering therapies. “There is a clear need to review the way in which exogenous insulin is used in people with type 2 diabetes and to establish in detail the risk-benefit profile at differing stages of the natural history of the disease and in phenotypically different subgroups,” researchers wrote in the Journal of Clinical Endocrinology and Metabolism.

Leave Comment

Your email address will not be published. Required fields are marked *

clear formSubmit